Allen Avedian
Internal Medicine · Templeton, CANPI 1003340423
Payments from drug & device makers
Across 216 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$740
- AbbVie$733
- Novo Nordisk$434
- Lilly USA, LLC$385
- Amgen$226
- Pfizer$197
- plus $957 from 13 others
What the payments were for
- Food & beverage$3,671100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 56 | $740 |
| AbbVie | 51 | $733 |
| Novo Nordisk | 24 | $434 |
| Lilly USA, LLC | 21 | $385 |
| Amgen | 7 | $226 |
| Pfizer | 11 | $197 |
| Otsuka America Pharmaceutical, Inc. | 8 | $180 |
| Exact Sciences | 6 | $137 |
| Boehringer Ingelheim | 5 | $96 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Bayer | 4 | $85 |
| Novartis | 3 | $80 |
| Merck | 4 | $72 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Johnson & Johnson | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,671 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $85,513 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $65,897 |
| OzempicSemaglutide | 44 | $44,719 |
| RybelsusSemaglutide | 27 | $38,638 |
| JardianceEmpagliflozin | 27 | $31,958 |
| XareltoRivaroxaban | 22 | $22,823 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $22,238 |
| JanuviaSitagliptin Phosphate | 11 | $16,089 |
| Spiriva RespimatTiotropium Bromide | 21 | $11,451 |
| Atorvastatin Calcium | 598 | $8,527 |
| InvokanaCanagliflozin | 12 | $8,156 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $7,598 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $6,632 |
| Levothyroxine Sodium | 404 | $6,398 |
| TrulicityDulaglutide | 11 | $5,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $740 | $88,135123 claims |
| PfizerEliquis | $197 | $85,51391 claims |
| Novo NordiskOzempic, Rybelsus | $434 | $83,35771 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy Xr | $96 | $50,04159 claims |
| Johnson & JohnsonXarelto, Invokana | $30 | $30,97934 claims |
| MerckJanuvia | $72 | $16,08911 claims |
| Lilly USA, LLCTrulicity | $385 | $5,80311 claims |
| Sanofi-aventis U.S. LLCLantus | $85 | $1,94320 claims |
| AbbVieSynthroid | $733 | $1,36622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Templeton
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.